Recurrent and Newly Diagnosed Glioblastoma: BeiGene BGB-290 Study
This study is to evaluate the safety, efficacy and clinical activity of BGB-290 in combination with radiation therapy (RT) and/or temozolomide (TMZ) in subjects with newly diagnosed or recurrent/refractory glioblastoma.
Study Enrollment
If you, your family member or loved one is interested in learning more about participating in this study, please contact the BeiGene Study Coordinator at
520-320-2157.